Underweight CL with 35-40% trim near $88.77; unanimous bearish direction with sizing debate resolved per 9/3 lesson
Underweight rating reflects unanimous directional bearish consensus across all three risk analysts and Research Manager. The 35-40% trim sizing honors the 9/3 reflection instructing default toward aggressive sizing (vs. 8/31's 60-65% retention as the empirically verified alpha sweet spot). Key bearish catalysts include: 22.8x forward P/E vs. 20x five-year average, simultaneous breakdown below 10 EMA/50 SMA/30-day VWMA, MACD bearish and expanding, RSI at 40.3, Bollinger Band tag reading as bandwidth expansion rather than reversal, September 21 S&P 100 rebalance supply, unfavorable 5% money market yield vs. CL's 2.39%, and PG's 8% FY27 EPS headwind transmission risk. Full Sell is rejected due to the structural franchise value (60+ year dividend streak, $3.46B FCF covering $3.11B capital return with $390M cushion). Re-entry requires all three: close >$91.10, RSI >50, MACD histogram contracting, and volume >3.5M.
| Position | Action |
|---|---|
| Technical, fundamental, and sector-level signals aligned near 52-week-high resistance | Default toward Aggressive Analyst's sizing (35-40% trim executed) |
Colgate-Palmolive is a classic mean reversion opportunity at the lower Bollinger Band with 3.1:1 reward-to-risk, backed by $3.46B annual FCF funding a 62-year Dividend King status and aggressive capital return (dividends + buybacks + deleveraging simultaneously).
| Indicator | Value | Signal |
|---|---|---|
| Close | $88.77 | neutral |
| 10 EMA | $90.25 | bearish |
| 50 SMA | $91.67 | bearish |
| 200 SMA | $86.94 | bullish |
| RSI (14) | 40.30 | neutral |
| MACD | −0.55 | bearish |
| MACD Signal | −0.29 | bearish |
| MACD Histogram | −0.25 | bearish |
| Bollinger Mid (20 SMA) | $91.10 | bearish |
| Bollinger Upper Band | $93.56 | bearish |
| Bollinger Lower Band |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
P/E premium is justified by recession-resistant cash flow quality
EV: +2.6% base case / +5.4% bull case (expected return) · concedes: Bear's 'wait for confirmation above $91.10' costs buying 3% higher; Forward P/E at 22.8x is above 5-year average of ~20x; S&P 100 rebalance creates 1-3 days of selling pressure; Sept 21 index change is real passive-flow drag
The risk/reward is asymmetrically skewed against new buyers at current levels — quality at the wrong price is still a bad trade.
· concedes: The stock has declined recently from higher levels; The earnings recovery from Q4 2025 charges is underway; The dividend remains secure; Valuation is slightly below the 5-year average at 22.8x forward P/E; FCF of $3.5B annually is substantial
→ vs conservative: The conservative view holds because the franchise is great, but that argument was also true three months ago at $95 when the stock is now down 7%; great companies can be mediocre trades at elevated multiples, and active risk management requires recognizing when that distinction matters
→ vs neutral: The neutral analyst points to the 200-day moving average at $86.94 as a structural floor justifying patience, but this is a lagging indicator being used as psychological anchor; price has already failed at 10 EMA, 50 SMA, and 30-day VWAP with MACD bearish and expanding
→ vs neutral: The neutral analyst acknowledges the September 21 passive flow event as a bearish catalyst but still recommends holding through it; that is contradictory—mechanical selling pressure will hit regardless of preference, and trimming ahead of known supply is position management while holding through it is inertia
→ vs neutral: The lower Bollinger Band tag is not a reversal zone warranting patience; it is worth nothing until CL closes back above mid-band at $91.10 with RSI above 50 and contracting MACD histogram
→ vs conservative: Trimming 25-50% into weakness is not locking in losses, it is correcting position sizing in a regime where the asymmetry has shifted against us; we are reducing the bet that CL holds its premium multiple through a passive flow event, competitive incursion, and sector-wide margin warning
| $88.65 |
| neutral |
| ATR (14) | $1.78 | neutral |
| VWMA (30) | ~$90.73 | bearish |
Support: 88.65 · 86.94 · 84.49 · 81.34 | Resistance: 90.25 · 90.73 · 91.1 · 91.67 · 93.56
Bearish near-term consolidation with neutral long-term backdrop. Price at fresh 30-day low ($88.77) has broken below both 10 EMA ($90.25) and 50 SMA ($91.67), confirming short- and intermediate-term weakness; however, the 200 SMA ($86.94) remains intact, preserving the secular uptrend from spring 2025. RSI of 40.30 is weak but not oversold, MACD has completed a bearish crossover with histogram expanding at −0.25, and VWMA has declined from $92.23 (Aug 14) to ~$90.73, confirming selling pressure on declining days. ATR of $1.78 suggests moderate volatility (≈2.0% daily range), and the current close sits just above the lower Bollinger Band ($88.65), creating a mean-reversion watch zone that lacks bullish confirmation. Key levels: resistance at $91.10 (mid-band reclaim = first bullish signal) and $91.67 (50 SMA, primary trend gate); critical support at $86.94 (200 SMA loss = structural break). Risk/reward for tactical shorts targeting $86.94 with stop above $91.67 is ≈1.7:1.
Market Cap
$70.48B
Shares Outstanding
~800 million
PE Ratio (TTM)
34.81x
Forward PE
21.52x
PEG Ratio
1.62
Price / Book
298.7x
EPS (TTM)
$2.54
Forward EPS
$4.11
Dividend Yield
2.39%
Beta
0.32
52-Week High
$99.33
52-Week Low
$74.55
50-Day MA
$91.83
200-Day MA
$87.72
Revenue (TTM)
$21.05B
Gross Margin (TTM)
~60.4%
Operating Margin
20.97%
Profit Margin
9.68%
EBITDA (TTM)
$4.98B
ROE
267.4%
ROA
15.8%
Total Assets
$16.79B
Total Debt
$7.86B
Net Debt
$6.49B
Stockholders' Equity
$0.24B
Treasury Stock
$28.93B
Free Cash Flow (TTM)
$3.46B
FCF Yield
~4.9%
Dividends Paid (TTM)
~$1.85B
Buybacks (TTM)
~$1.2B
Current Ratio
1.03
CapEx as % of Revenue
~2.4%
Q2 2026 Revenue
$5,361M
Q2 2026 YoY Revenue Growth
+4.9%
Q2 2026 Diluted EPS
$0.86
Q4 2025 One-Time Charge
$866M
Q2 2026 Operating Cash Flow
$995M
Q2 2026 Free Cash Flow
$867M
Strengths
Concerns
Colgate-Palmolive is a high-quality defensive consumer staples franchise with strong cash generation ($3.46B TTM FCF) and a 2.39% dividend yield backed by a 62-year dividend growth streak. The forward valuation of ~21.5x PE is reasonable but not cheap, with TTM metrics distorted by an $866M one-time Q4 2025 charge that artificially suppressed EPS to $2.54 vs. forward $4.11. The stock has pulled back ~11% from 52-week highs and is consolidating near the 200-day moving average, presenting a potential accumulation opportunity on further weakness toward $87-88. With a beta of 0.32 and FCF yield of ~4.9%, CL is best suited as a long-term defensive anchor rather than a high-growth performer.
Macro: Polymarket-implied odds show 93% probability of no Fed cuts in 2026 (up +4pp WoW), with recession odds at only 8% — a soft-landing consensus that supports staples multiples but leaves CL's 22.8x forward P/E stretched vs. its ~20x 5-year average. Soft-landing odds at 56% (down 3.5pp WoW) are eroding while overheating odds at 40% (up 7pp WoW) suggest sticky inflation. Commodity headwinds include firmer oil (OPEC+ pause, Iran-Israel tensions, Venezuela policy shift) partially offset by lower sugar prices on smaller Indian imports.